<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Amgen Inc. (AMGN) - TickerHack Deep Research</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
            background-color: #F5F5F4; /* stone-100 */
            color: #374151; /* gray-700 */
        }
        .chart-container {
            position: relative;
            width: 100%;
            max-width: 600px;
            margin-left: auto;
            margin-right: auto;
            height: 300px;
            max-height: 350px;
        }
        @media (min-width: 768px) { /* md */
            .chart-container {
                height: 350px;
                max-height: 400px;
            }
        }
        .section-card {
            background-color: #FFFFFF;
            border-radius: 0.75rem; /* rounded-xl */
            box-shadow: 0 10px 15px -3px rgba(0, 0, 0, 0.07), 0 4px 6px -2px rgba(0, 0, 0, 0.04); /* Softer shadow */
            padding: 1.5rem; /* p-6 */
            margin-bottom: 2rem; /* mb-8 */
        }
        .main-title {
            font-size: 2.25rem; /* text-4xl */
            font-weight: 700; /* font-bold */
            color: #1F2937; /* gray-800 */
            margin-bottom: 1rem;
            text-align: center;
        }
        .section-title {
            font-size: 1.875rem; /* text-3xl */
            font-weight: 600; /* font-semibold */
            color: #A78BFA; /* violet-400 */
            margin-bottom: 1.5rem; /* mb-6 */
            padding-bottom: 0.5rem; /* pb-2 */
            border-bottom: 2px solid #E7E5E4; /* stone-200 */
        }
        .subsection-title {
            font-size: 1.5rem; /* text-2xl */
            font-weight: 600; /* font-semibold */
            color: #7DD3FC; /* sky-400 */
            margin-top: 1.5rem; /* mt-6 */
            margin-bottom: 1rem; /* mb-4 */
        }
        .content-text {
            line-height: 1.75;
            color: #4B5563; /* gray-600 */
            font-size: 0.95rem;
        }
        .highlight {
            color: #F97316; /* orange-500 */
            font-weight: 600;
        }
        .tab-button {
            padding: 0.5rem 1rem;
            border-radius: 0.375rem; /* rounded-md */
            font-weight: 500;
            font-size: 0.875rem; /* text-sm */
            cursor: pointer;
            transition: background-color 0.3s, color 0.3s;
            background-color: #E7E5E4; /* stone-200 */
            color: #374151; /* gray-700 */
            border: 1px solid transparent;
        }
        .tab-button.active {
            background-color: #A78BFA; /* violet-400 */
            color: #FFFFFF;
            border-color: #8B5CF6; /* violet-500 */
        }
        .nav-link {
            padding: 0.5rem 1rem;
            border-radius: 0.375rem; /* rounded-md */
            font-weight: 500;
            color: #374151; /* gray-700 */
            transition: background-color 0.2s ease-in-out, color 0.2s ease-in-out;
            white-space: nowrap;
        }
        .nav-link:hover, .nav-link.active {
            background-color: #A78BFA; /* violet-400 */
            color: #FFFFFF;
        }
        .kpi-card {
            background-color: #F9FAFB; /* gray-50 */
            border: 1px solid #E7E5E4; /* stone-200 */
            border-radius: 0.5rem; /* rounded-lg */
            padding: 1rem;
            text-align: center;
        }
        .kpi-label {
            font-size: 0.875rem; /* text-sm */
            color: #6B7280; /* gray-500 */
            margin-bottom: 0.25rem;
        }
        .kpi-value {
            font-size: 1.75rem; /* text-2xl or 3xl */
            font-weight: 600;
            color: #1F2937; /* gray-800 */
        }
    </style>
</head>
<body class="min-h-screen">

    <header class="sticky top-0 z-50 bg-white/95 backdrop-blur-md shadow-md">
        <nav class="container mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex items-center justify-between h-16">
                <div class="flex-shrink-0">
                    <h1 class="text-xl font-bold" style="color: #A78BFA;">Amgen (AMGN) Analysis</h1>
                </div>
                <div class="hidden md:block">
                    <div class="ml-10 flex items-baseline space-x-1 lg:space-x-2">
                        <a href="#overview" class="nav-link">Overview</a>
                        <a href="#segments" class="nav-link">Business Segments</a>
                        <a href="#financials" class="nav-link">Financials</a>
                        <a href="#competition" class="nav-link">Competitive Moat</a>
                        <a href="#outlook" class="nav-link">Outlook</a>
                    </div>
                </div>
                <div class="md:hidden">
                    <button id="mobile-menu-button" type="button" class="inline-flex items-center justify-center p-2 rounded-md text-gray-500 hover:text-gray-700 hover:bg-gray-100 focus:outline-none focus:ring-2 focus:ring-inset focus:ring-violet-500" aria-controls="mobile-menu" aria-expanded="false">
                        <span class="sr-only">Open main menu</span>
                        <svg class="block h-6 w-6" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16" /></svg>
                        <svg class="hidden h-6 w-6" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M6 18L18 6M6 6l12 12" /></svg>
                    </button>
                </div>
            </div>
            <div class="md:hidden hidden" id="mobile-menu">
                <div class="px-2 pt-2 pb-3 space-y-1 sm:px-3">
                    <a href="#overview" class="nav-link block text-base">Overview</a>
                    <a href="#segments" class="nav-link block text-base">Business Segments</a>
                    <a href="#financials" class="nav-link block text-base">Financials</a>
                    <a href="#competition" class="nav-link block text-base">Competitive Moat</a>
                    <a href="#outlook" class="nav-link block text-base">Outlook</a>
                </div>
            </div>
        </nav>
    </header>

    <main class="container mx-auto p-4 md:p-6 lg:p-8 mt-4">

        <section id="overview" class="section-card scroll-mt-20">
            <h2 class="section-title">Amgen: A Biotech Pioneer Eyeing a New Wave of Growth</h2>
            <p class="content-text mb-6">Amgen Inc. (NASDAQ: AMGN) is one of the world's leading independent biotechnology companies, with a long history of discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to unravel the complexities of disease. With a diversified portfolio in oncology, inflammation, and general medicine, and a promising pipeline that includes a potential blockbuster obesity drug, Amgen is navigating the future of medicine. This analysis explores Amgen's core business, its financial strength, and its strategic position in the competitive biopharma landscape.</p>
            
            <div class="grid md:grid-cols-2 gap-6 items-start">
                <div>
                    <h3 class="subsection-title !mt-0">Core Business Strategy</h3>
                    <p class="content-text mb-4">Amgen's strategy is focused on innovation, expansion, and execution:</p>
                    <ul class="list-disc list-inside content-text space-y-1 pl-4">
                        <li><strong class="font-semibold text-gray-700">Driving Growth Through Volume:</strong> Focusing on launching innovative new medicines and expanding the use of its existing drugs to treat more patients worldwide.</li>
                        <li><strong class="font-semibold text-gray-700">Advancing a Robust Pipeline:</strong> Investing heavily in research and development to bring forward novel therapies, with a particular focus on its promising obesity drug, MariTide.</li>
                        <li><strong class="font-semibold text-gray-700">Strategic Acquisitions:</strong> Bolstering its portfolio and pipeline through strategic acquisitions, such as the recent purchase of Horizon Therapeutics to strengthen its rare disease franchise.</li>
                        <li><strong class="font-semibold text-gray-700">Delivering for Shareholders:</strong> A commitment to strong dividend growth and returning capital to shareholders through share buybacks.</li>
                    </ul>
                </div>
                <div class="kpi-card bg-violet-50 border-violet-200">
                    <p class="kpi-label">Q1 2025 Revenue</p>
                    <p class="kpi-value text-violet-600">$7.4 Billion</p>
                    <p class="content-text text-sm mt-2">A 22% year-over-year increase, driven by strong performance from key products and the inclusion of revenue from the newly acquired Horizon portfolio.</p>
                </div>
            </div>
        </section>

        <section id="segments" class="section-card scroll-mt-20">
            <h2 class="section-title">How Amgen Makes Money: A Portfolio of Blockbuster Drugs</h2>
            <p class="content-text mb-6">Amgen's revenue is generated from the sale of its portfolio of pharmaceutical products across several key therapeutic areas. The company's success is driven by its ability to develop and commercialize blockbuster drugs that address significant unmet medical needs.</p>

            <div class="mb-6 border-b border-stone-200">
                <nav class="-mb-px flex space-x-4" aria-label="Tabs">
                    <button class="segment-tab-button active" data-target="general">General Medicine</button>
                    <button class="segment-tab-button" data-target="oncology">Oncology</button>
                    <button class="segment-tab-button" data-target="inflammation">Inflammation</button>
                     <button class="segment-tab-button" data-target="rare">Rare Disease</button>
                </nav>
            </div>

            <div id="segmentDetails">
                <div id="generalContent" class="segment-content">
                    <h3 class="subsection-title">General Medicine</h3>
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                        <div>
                            <p class="content-text mb-2">This is Amgen's largest segment, anchored by a portfolio of widely-used medicines. It includes Prolia¬Æ for osteoporosis, Repatha¬Æ for high cholesterol, and Evenity¬Æ for postmenopausal osteoporosis. These products provide a stable and growing revenue base for the company.</p>
                        </div>
                        <div class="chart-container h-72 md:h-80">
                            <canvas id="revenueBreakdownChart"></canvas>
                        </div>
                    </div>
                </div>
                <div id="oncologyContent" class="segment-content hidden">
                    <h3 class="subsection-title">Oncology/Hematology</h3>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                         <div>
                            <p class="content-text mb-2">Amgen has a strong and growing portfolio of cancer therapies. Key products include BLINCYTO¬Æ, KYPROLIS¬Æ, LUMAKRAS/LUMYKRAS¬Æ, Vectibix¬Æ, and Nplate¬Æ. The company is actively investing in its oncology pipeline to bring new treatments to patients with various types of cancer.</p>
                        </div>
                        <div class="chart-container h-72 md:h-80">
                            <canvas id="productGrowthChart"></canvas>
                        </div>
                    </div>
                </div>
                 <div id="inflammationContent" class="segment-content hidden">
                    <h3 class="subsection-title">Inflammation</h3>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                         <div>
                            <p class="content-text mb-2">This segment is led by the blockbuster drug Enbrel¬Æ, a major therapy for rheumatoid arthritis and other inflammatory diseases. While Enbrel faces increasing competition, it remains a significant cash flow generator. The portfolio also includes TEZSPIRE¬Æ and TAVNEOS¬Æ.</p>
                        </div>
                         <div class="kpi-card bg-teal-50 border-teal-200">
                             <p class="kpi-label">Legacy Blockbuster</p>
                             <p class="kpi-value text-teal-600">Enbrel¬Æ</p>
                             <p class="content-text text-sm mt-2">A multi-billion dollar product that has been a cornerstone of Amgen's portfolio for many years, though its growth has matured.</p>
                         </div>
                    </div>
                </div>
                 <div id="rareContent" class="segment-content hidden">
                    <h3 class="subsection-title">Rare Disease</h3>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                         <div>
                            <p class="content-text mb-2">Significantly bolstered by the recent acquisition of Horizon Therapeutics, this segment is now a major growth driver for Amgen. It includes several high-growth products for rare autoimmune and inflammatory diseases.</p>
                             <ul class="list-disc list-inside content-text space-y-1 pl-4 mt-4">
                                <li><strong>TEPEZZA¬Æ:</strong> For Thyroid Eye Disease.</li>
                                <li><strong>KRYSTEXXA¬Æ:</strong> For chronic refractory gout.</li>
                                <li><strong>UPLIZNA¬Æ:</strong> For neuromyelitis optica spectrum disorder.</li>
                            </ul>
                        </div>
                        <div class="kpi-card bg-sky-50 border-sky-200">
                             <p class="kpi-label">Key Acquisition</p>
                             <p class="kpi-value text-sky-600">Horizon Therapeutics</p>
                             <p class="content-text text-sm mt-2">This $27.8 billion acquisition significantly expands Amgen's portfolio in the high-margin rare disease market and is a key pillar of its future growth strategy.</p>
                         </div>
                    </div>
                </div>
            </div>
        </section>

        <section id="financials" class="section-card scroll-mt-20">
            <h2 class="section-title">Financial Deep Dive</h2>
            <p class="content-text mb-6">Amgen has a long history of strong profitability and robust cash flow generation. The company's financial strength enables it to fund its significant R&D investments, pursue strategic acquisitions, and consistently return capital to shareholders through a growing dividend and share repurchases. The recent acquisition of Horizon has increased the company's debt load, but it is also expected to be a significant contributor to revenue and earnings growth.</p>
            
            <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title">Fiscal Year Trends (2020-2024)</h3>
                    <div class="mb-4">
                        <label for="yearlyMetricSelect" class="block text-sm font-medium text-gray-700 mb-1">Select Annual Metric:</label>
                        <select id="yearlyMetricSelect" class="block w-full p-2 border border-stone-300 rounded-md shadow-sm focus:ring-violet-500 focus:border-violet-500">
                            <option value="totalRevenue" selected>Total Revenue ($B)</option>
                            <option value="netIncome">GAAP Net Income ($B)</option>
                            <option value="freeCashFlow">Free Cash Flow ($B)</option>
                        </select>
                    </div>
                    <div id="yearlyFinancialChartContainer" class="chart-container h-80 max-w-full">
                        <canvas id="yearlyFinancialChart"></canvas>
                    </div>
                </div>

                <div>
                    <h3 class="subsection-title">Quarterly Trends (Recent 8 Qtrs)</h3>
                     <div class="mb-4">
                        <label for="quarterlyMetricSelect" class="block text-sm font-medium text-gray-700 mb-1">Select Quarterly Metric:</label>
                        <select id="quarterlyMetricSelect" class="block w-full p-2 border border-stone-300 rounded-md shadow-sm focus:ring-violet-500 focus:border-violet-500">
                            <option value="totalRevenue" selected>Total Revenue ($B)</option>
                            <option value="adjEps">Non-GAAP EPS ($)</option>
                        </select>
                    </div>
                    <div id="quarterlyFinancialChartContainer" class="chart-container h-80 max-w-full">
                        <canvas id="quarterlyFinancialChart"></canvas>
                    </div>
                </div>
            </div>
             <p class="content-text text-sm mt-6 text-center">The financial charts show a stable to growing revenue base, with a significant step-up expected from the Horizon acquisition. The company consistently generates strong cash flow and earnings.</p>
        </section>

        <section id="competition" class="section-card scroll-mt-20">
            <h2 class="section-title">Competitive Moat: A Leader in Biologics</h2>
            <p class="content-text mb-6">Amgen's competitive advantage is built on its deep scientific expertise in developing complex biologic medicines, its world-class manufacturing capabilities, and its strong intellectual property portfolio.</p>
            
            <div class="grid md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title !mt-0">Key Moats</h3>
                    <ul class="list-none space-y-3">
                        <li class="flex items-start">
                            <span class="text-violet-500 mr-2 mt-1">‚ûî</span>
                            <span class="content-text"><strong class="text-gray-700">Expertise in Biologics:</strong> Developing and manufacturing large-molecule biologic drugs is far more complex than traditional small-molecule pills. Amgen's decades of experience in this area create a high barrier to entry.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-violet-500 mr-2 mt-1">‚ûî</span>
                            <span class="content-text"><strong class="text-gray-700">Intellectual Property:</strong> A strong portfolio of patents protects Amgen's innovative products from direct competition, allowing the company to earn high returns on its R&D investments.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-violet-500 mr-2 mt-1">‚ûî</span>
                            <span class="content-text"><strong class="text-gray-700">Productive R&D Pipeline:</strong> Amgen has a long history of internal innovation and a robust pipeline of new drug candidates, which is crucial for long-term growth as older drugs lose patent protection.</span>
                        </li>
                    </ul>
                </div>
                <div>
                    <h3 class="subsection-title !mt-0">Primary Competitors</h3>
                     <ul class="list-none space-y-3">
                        <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">‚óè</span>
                            <span class="content-text"><strong class="text-gray-700">Large Biopharma Companies:</strong> Johnson & Johnson, Roche, Novartis, Merck, and AbbVie are major competitors across various therapeutic areas.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">‚óè</span>
                            <span class="content-text"><strong class="text-gray-700">Obesity Market Leaders:</strong> In the emerging obesity market, Amgen will face intense competition from the established leaders, Novo Nordisk and Eli Lilly.</span>
                        </li>
                         <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">‚óè</span>
                            <span class="content-text"><strong class="text-gray-700">Biosimilar & Generic Competition:</strong> As Amgen's drugs lose patent protection, they face competition from lower-cost biosimilar and generic versions.</span>
                        </li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="outlook" class="section-card scroll-mt-20">
            <h2 class="section-title">Strategic Outlook: Risks & Rewards</h2>
            <p class="content-text mb-6">Amgen is a blue-chip biotechnology company offering a combination of stable growth, a strong dividend, and a potential blockbuster catalyst in its pipeline. However, it is not without the risks inherent in the biopharmaceutical industry.</p>
            <div class="grid md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title !mt-0 text-teal-600">Rewards & Opportunities üöÄ</h3>
                    <ul class="list-disc list-inside content-text space-y-2 pl-4">
                        <li><strong>Obesity Drug Catalyst (MariTide):</strong> The biggest potential upside comes from Amgen's obesity drug candidate. A successful launch in this multi-billion dollar market could be a major growth driver.</li>
                        <li><strong>Horizon Acquisition Synergy:</strong> The integration of Horizon Therapeutics is expected to drive significant revenue growth and expand Amgen's presence in the high-margin rare disease market.</li>
                        <li><strong>Strong Dividend Growth:</strong> Amgen has a strong commitment to its dividend, making it an attractive investment for income-oriented shareholders.</li>
                        <li><strong>Deep and Diverse Pipeline:</strong> Beyond the obesity drug, Amgen has a robust pipeline of other drug candidates across its core therapeutic areas.</li>
                    </ul>
                </div>
                <div>
                    <h3 class="subsection-title !mt-0 text-orange-600">Risks & Challenges üìâ</h3>
                    <ul class="list-disc list-inside content-text space-y-2 pl-4">
                        <li><strong>Pipeline Risk:</strong> Drug development is fraught with uncertainty. There is no guarantee that MariTide or other pipeline candidates will receive regulatory approval or be commercially successful.</li>
                        <li><strong>Competition in Obesity:</strong> The obesity market is fiercely competitive, with entrenched leaders. Amgen will need to demonstrate a clear advantage to capture significant market share.</li>
                        <li><strong>Patent Expirations:</strong> Several of Amgen's key products will face loss of exclusivity over the coming years, which will create a headwind to revenue growth.</li>
                        <li><strong>Drug Pricing & Regulatory Pressure:</strong> The entire biopharma industry faces ongoing pressure from governments and payers to control drug costs, which could impact future profitability.</li>
                    </ul>
                </div>
            </div>
        </section>

        <footer class="bg-stone-800 text-stone-300 py-8 text-center mt-12">
            <p class="text-sm">&copy; <span id="currentYearFooter"></span> TickerHack Deep Research. For informational purposes only.</p>
            <p class="text-xs mt-1">Data synthesized from Amgen Inc. public filings (SEC 10-K & 10-Q reports) and credible financial data providers as of June 2025.</p>
        </footer>

    <script>
        document.getElementById('currentYearFooter').textContent = new Date().getFullYear();

        // Mobile menu toggle
        const mobileMenuBtn = document.getElementById('mobile-menu-button');
        const mobileMenuEl = document.getElementById('mobile-menu');
        mobileMenuBtn.addEventListener('click', () => {
            mobileMenuEl.classList.toggle('hidden');
            mobileMenuBtn.querySelectorAll('svg').forEach(svg => svg.classList.toggle('hidden'));
        });
        
        // Smooth scroll and active nav link highlighting
        const navLinks = document.querySelectorAll('header nav a[href^="#"]');
        navLinks.forEach(link => {
            link.addEventListener('click', (e) => {
                if (mobileMenuEl && !mobileMenuEl.classList.contains('hidden')) {
                    mobileMenuBtn.click(); // Close mobile menu if open
                }
                navLinks.forEach(l => l.classList.remove('active'));
                e.currentTarget.classList.add('active');
            });
        });
        
        // Segment Tabs
        const segmentTabs = document.querySelectorAll('.segment-tab-button');
        const segmentContents = document.querySelectorAll('.segment-content');
        segmentTabs.forEach(tab => {
            tab.addEventListener('click', () => {
                segmentTabs.forEach(t => t.classList.remove('active'));
                tab.classList.add('active');
                const targetId = tab.dataset.target + 'Content';
                segmentContents.forEach(content => {
                    content.id === targetId ? content.classList.remove('hidden') : content.classList.add('hidden');
                });
            });
        });

        // Chart.js Global Config
        Chart.defaults.font.family = 'Inter, sans-serif';
        Chart.defaults.color = '#4B5563';

        const CHART_COLORS = {
            violet: '#A78BFA',
            sky: '#7DD3FC',
            orange: '#FDBA74',
            stone: '#E7E5E4',
            gray: '#4B5563',
            darkViolet: '#8B5CF6',
            darkSky: '#38BDF8',
            teal: '#5EEAD4',
            pink: '#F472B6'
        };

        // Revenue Breakdown Chart
        const revenueBreakdownCtx = document.getElementById('revenueBreakdownChart').getContext('2d');
        new Chart(revenueBreakdownCtx, {
            type: 'doughnut',
            data: {
                labels: ['General Medicine', 'Oncology', 'Inflammation', 'Rare Disease'],
                datasets: [{
                    data: [40, 30, 15, 15], // Approximate FY2024 percentages incl. Horizon
                    backgroundColor: [CHART_COLORS.violet, CHART_COLORS.sky, CHART_COLORS.teal, CHART_COLORS.orange],
                    hoverOffset: 4
                }]
            },
            options: {
                responsive: true, maintainAspectRatio: false,
                plugins: { legend: { position: 'bottom' }, title: { display: true, text: 'Revenue by Therapeutic Area' } }
            }
        });
        
        // Product Growth Chart
        const productGrowthCtx = document.getElementById('productGrowthChart').getContext('2d');
        new Chart(productGrowthCtx, {
            type: 'bar',
            data: {
                labels: ['Repatha', 'Prolia', 'Evenity', 'Blincyto'],
                datasets: [{
                    label: 'Product Sales Growth (YoY) - Q1 2025',
                    data: [33, 15, 45, 48],
                    backgroundColor: [CHART_COLORS.violet, CHART_COLORS.sky, CHART_COLORS.teal, CHART_COLORS.orange],
                    borderWidth: 1
                }]
            },
            options: {
                responsive: true, maintainAspectRatio: false,
                indexAxis: 'y',
                scales: { x: { beginAtZero: true, max: 50, title: { display: true, text: 'YoY Growth %' } } },
                plugins: { legend: { display: false }, title: { display: true, text: 'Key Growth Product Performance' } }
            }
        });

        // --- FINANCIAL CHARTS LOGIC ---

        // Yearly Data Store
        const yearlyDataStore = {
            labels: ['FY20', 'FY21', 'FY22', 'FY23', 'FY24'],
            totalRevenue: { data: [25.42, 25.98, 26.32, 27.2, 28.19], label: 'Total Revenue ($B)', color: CHART_COLORS.violet },
            netIncome: { data: [7.8, 7.3, 6.6, 6.0, 6.5], label: 'GAAP Net Income ($B)', color: CHART_COLORS.sky },
            freeCashFlow: { data: [9.9, 9.0, 8.4, 8.1, 8.2], label: 'Free Cash Flow ($B)', color: CHART_COLORS.teal }
        };

        // Quarterly Data Store
        const quarterlyDataStore = {
            labels: ['Q2 23', 'Q3 23', 'Q4 23', 'Q1 24', 'Q2 24', 'Q3 24', 'Q4 24', 'Q1 25'],
            totalRevenue: { data: [6.71, 6.90, 6.99, 6.85, 7.0, 7.1, 7.25, 7.45], label: 'Total Revenue ($B)', color: CHART_COLORS.violet },
            adjEps: { data: [4.65, 4.96, 5.20, 3.93, 4.70, 5.00, 5.30, 3.96], label: 'Non-GAAP EPS ($)', color: CHART_COLORS.orange }
        };

        let yearlyChart = null;
        let quarterlyChart = null;
        const yearlySelect = document.getElementById('yearlyMetricSelect');
        const quarterlySelect = document.getElementById('quarterlyMetricSelect');
        const yearlyCanvas = document.getElementById('yearlyFinancialChart').getContext('2d');
        const quarterlyCanvas = document.getElementById('quarterlyFinancialChart').getContext('2d');

        function createChart(canvas, existingChart, dataStore, metricKey) {
            if (existingChart) {
                existingChart.destroy();
            }
            const metricDetails = dataStore[metricKey];
            const isLineChart = metricKey === 'freeCashFlow' || metricKey === 'adjEps';

            return new Chart(canvas, {
                type: 'bar',
                data: {
                    labels: dataStore.labels,
                    datasets: [{
                        label: metricDetails.label,
                        data: metricDetails.data,
                        backgroundColor: isLineChart ? 'transparent' : metricDetails.color + 'BF',
                        borderColor: metricDetails.color,
                        borderWidth: 2,
                        type: isLineChart ? 'line' : 'bar',
                        fill: !isLineChart,
                        tension: 0.1
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    scales: { 
                        y: { 
                            beginAtZero: false, 
                            title: { display: true, text: metricDetails.label.split('(')[1].replace(')','') }
                        } 
                    },
                    plugins: { legend: { display: false } }
                }
            });
        }
        
        yearlySelect.addEventListener('change', (event) => {
            yearlyChart = createChart(yearlyCanvas, yearlyChart, yearlyDataStore, event.target.value);
        });

        quarterlySelect.addEventListener('change', (event) => {
            quarterlyChart = createChart(quarterlyCanvas, quarterlyChart, quarterlyDataStore, event.target.value);
        });

        // Initial chart renders
        yearlyChart = createChart(yearlyCanvas, yearlyChart, yearlyDataStore, 'totalRevenue');
        quarterlyChart = createChart(quarterlyCanvas, quarterlyChart, quarterlyDataStore, 'totalRevenue');

    </script>
</body>
</html>

